Pharma-Biotech Product & Company Valuation

AN INTRODUCTORY COURSE

With Dr Patrik Frei

THE CONTENT

In the high-stakes world of pharma and biotech, traditional valuation methods often fail to capture the realities of the industry. Unique factors such as high R&D attrition rates, extended investment cycles, and complex IP landscapes demand a specialised approach.

This course provides a practical introduction to product and company valuation tailored specifically for the pharma and biotech sectors. You will learn the core concepts, tools, and techniques essential for financing rounds and investment decisions, as well as M&A, licensing deals and partnerships, strategic development planning, and portfolio optimisation.

By linking valuation theory to real industry scenarios, this course equips you with the knowledge and confidence to apply valuation concepts effectively!

WHAT YOU WILL LEARN

1. A methodology for assessing and optimising the risk profile of a life science company prior to valuation.
2. The different valuation methods used for life science companies and products.
3. How to calculate the value of a biotech or life science company using the Discounted Cash Flow method/rNPV, comparables, and Venture Capital method.
4. How to use risk-adjusted Net Present Value (rNPV) to calculate the value of a pharmaceutical compound in development.
5. How to structure the licensing deal between companies, covering issues such as milestone and royalty payments.